[go: up one dir, main page]

PE20180498A1 - Inmunoglobulinas conjugadas en cys80 - Google Patents

Inmunoglobulinas conjugadas en cys80

Info

Publication number
PE20180498A1
PE20180498A1 PE2017002753A PE2017002753A PE20180498A1 PE 20180498 A1 PE20180498 A1 PE 20180498A1 PE 2017002753 A PE2017002753 A PE 2017002753A PE 2017002753 A PE2017002753 A PE 2017002753A PE 20180498 A1 PE20180498 A1 PE 20180498A1
Authority
PE
Peru
Prior art keywords
seq
amino acids
cys80
immunoglobulins
variable region
Prior art date
Application number
PE2017002753A
Other languages
English (en)
Inventor
Luigi Grasso
Jared Spidel
James Bradford Kline
Earl Albone
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20180498A1 publication Critical patent/PE20180498A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A INMUNOGLOBULINAS QUE COMPRENDEN: A) UNA REGION VARIABLE DE LA CADENA PESADA QUE TIENE UNA SECUENCIA DE AMINOACIDOS 90% IDENTICA A LOS AMINOACIDOS 20-139 DE LA SEQ ID N°: 56, CUYAS CDR1, CDR2 Y CDR3 COMPRENDEN LAS SECUENCIAS DE SEQ ID N°: 158, 160 Y 162, RESPECTIVAMENTE; Y B) UNA REGION VARIABLE DE LA CADENA LIVIANA QUE TIENE UNA SECUENCIA DE AMINOACIDOS 90% IDENTICA A LOS AMINOACIDOS 20-129 DE LA SEQ ID N°: 108, CUYAS CDR1, CDR2 Y CDR3 COMPRENDEN LAS SECUENCIAS DE SEQ ID N°: 314, 316 Y 318, RESPECTIVAMENTE. TAMBIEN SE REFIERE A METODOS PARA GENERAR INMUNOGLOBULINAS CONJUGADAS, QUE COMPRENDE: i) DESBLOQUEAR UNA CISTEINA EN LA POSICION DE AMINOACIDO 80 ("CYS80") EN UNA REGION VARIABLE DE LA CADENA LIVIANA DE UNA INMUNOGLOBULINA DERIVADA DE CONEJO; Y ii) CONJUGAR UN COMPUESTO QUE REACCIONA CON TIOL CON LA CYS80, EN DONDE DICHO COMPUESTO COMPRENDE UN GRUPO QUE REACCIONA CON TIOL. DICHAS INMUNOGLOBULINAS SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2017002753A 2015-06-19 2016-06-17 Inmunoglobulinas conjugadas en cys80 PE20180498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562182020P 2015-06-19 2015-06-19

Publications (1)

Publication Number Publication Date
PE20180498A1 true PE20180498A1 (es) 2018-03-09

Family

ID=56404289

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002753A PE20180498A1 (es) 2015-06-19 2016-06-17 Inmunoglobulinas conjugadas en cys80

Country Status (32)

Country Link
US (3) US10273310B2 (es)
EP (2) EP3310816B1 (es)
JP (2) JP6823606B2 (es)
KR (1) KR102718129B1 (es)
CN (1) CN107949575B (es)
AU (1) AU2016280190B9 (es)
CA (1) CA2989637C (es)
CL (1) CL2017003273A1 (es)
CO (1) CO2017013303A2 (es)
CY (1) CY1123481T1 (es)
DK (2) DK3795591T5 (es)
ES (2) ES2829251T3 (es)
HR (1) HRP20201489T1 (es)
HU (2) HUE064407T2 (es)
IL (1) IL256263B (es)
LT (1) LT3310816T (es)
MA (1) MA44207B1 (es)
MD (1) MD3310816T2 (es)
MX (1) MX389687B (es)
MY (1) MY189024A (es)
PE (1) PE20180498A1 (es)
PH (2) PH12017502352B1 (es)
PL (1) PL3310816T3 (es)
PT (1) PT3310816T (es)
RS (1) RS60943B1 (es)
RU (1) RU2756101C2 (es)
SG (1) SG10201913935RA (es)
SI (1) SI3310816T1 (es)
SM (1) SMT202000633T1 (es)
UA (2) UA124830C2 (es)
WO (1) WO2016205618A1 (es)
ZA (2) ZA201708619B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551036A1 (en) 2019-11-07 2023-05-29 Eisai R&D Man Co Ltd Anti-mesothelin eribulin antibody-drug conjugates and methods of use
JP7399305B2 (ja) * 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
CN116096752B (zh) 2020-06-05 2025-10-28 卫材R&D管理有限公司 抗bcma抗体-药物缀合物及其使用方法
CN112694521B (zh) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 一种人工多肽lh、其抗体及在病理检测中的应用
CN120813607A (zh) 2023-02-28 2025-10-17 卫材R&D管理有限公司 抗psma抗体、缀合物和使用方法
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507456A (en) * 1998-04-28 2003-10-31 Applied Research Systems Process and conjugated forms of PEGylated interferon- beta with polyethylene glycol (PEG) wherein the thiol reactive polyol agent is mono-methoxylated
US6904369B1 (en) * 2000-06-29 2005-06-07 The Trustees Of Columbia University In The City Of New York Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
CA2533830A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
CA2685213C (en) * 2007-05-04 2017-02-21 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
MX343879B (es) * 2007-05-21 2016-11-25 Alderbio Holdings Llc Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
MX2010007767A (es) * 2008-01-18 2010-08-09 Medimmune Llc Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
DK2842575T3 (da) 2008-03-18 2017-11-27 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
US20100260769A1 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
JP2013534520A (ja) * 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
EP2593142B8 (en) * 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
CA2882753C (en) 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
CA2879496C (en) * 2012-08-29 2024-01-09 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones

Also Published As

Publication number Publication date
CA2989637C (en) 2023-01-10
EP3795591B1 (en) 2023-09-27
UA124830C2 (uk) 2021-12-01
ES2967613T3 (es) 2024-05-03
AU2016280190A1 (en) 2018-01-18
HUE064407T2 (hu) 2024-03-28
ZA202102093B (en) 2023-03-29
AU2016280190B9 (en) 2022-05-19
RS60943B1 (sr) 2020-11-30
CA2989637A1 (en) 2016-12-22
CN107949575A (zh) 2018-04-20
MY189024A (en) 2022-01-20
CN107949575B (zh) 2022-03-08
AU2016280190B2 (en) 2022-04-28
CY1123481T1 (el) 2022-03-24
IL256263B (en) 2022-06-01
JP2020178717A (ja) 2020-11-05
MX389687B (es) 2025-03-20
ZA201708619B (en) 2022-11-30
SI3310816T1 (sl) 2020-12-31
US10273310B2 (en) 2019-04-30
CO2017013303A2 (es) 2018-03-20
KR102718129B1 (ko) 2024-10-17
SMT202000633T1 (it) 2021-01-05
DK3795591T5 (da) 2024-08-19
PH12017502352A1 (en) 2018-06-25
US20160369011A1 (en) 2016-12-22
HRP20201489T1 (hr) 2020-12-11
MD3310816T2 (ro) 2021-01-31
MA44207B1 (fr) 2020-11-30
EP3310816B1 (en) 2020-09-09
LT3310816T (lt) 2020-11-25
US20190202933A1 (en) 2019-07-04
RU2756101C2 (ru) 2021-09-28
ES2829251T3 (es) 2021-05-31
IL256263A (en) 2018-02-28
MA44207A (fr) 2018-12-26
EP3310816A1 (en) 2018-04-25
RU2017146220A3 (es) 2019-11-07
HUE051315T2 (hu) 2021-03-01
UA129321C2 (uk) 2025-03-19
PH12021551939A1 (en) 2022-05-02
WO2016205618A1 (en) 2016-12-22
NZ738496A (en) 2023-08-25
BR112017027252A2 (pt) 2018-08-28
KR20180021807A (ko) 2018-03-05
EP3795591A1 (en) 2021-03-24
PL3310816T3 (pl) 2020-12-14
PH12017502352B1 (en) 2023-05-26
US20230001004A1 (en) 2023-01-05
CL2017003273A1 (es) 2018-12-21
US11129904B2 (en) 2021-09-28
DK3310816T3 (da) 2020-10-12
JP7042876B2 (ja) 2022-03-28
PT3310816T (pt) 2020-10-19
JP6823606B2 (ja) 2021-02-03
SG10201913935RA (en) 2020-03-30
MX2017016674A (es) 2018-08-01
JP2018526975A (ja) 2018-09-20
RU2017146220A (ru) 2019-07-19
DK3795591T3 (da) 2024-01-02
HK1252625A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
PE20190737A1 (es) Anticuerpos anti-cd27
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20180498A1 (es) Inmunoglobulinas conjugadas en cys80
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
AR096687A1 (es) Anticuerpos anti-fcrh5
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
CL2015001895A1 (es) Anticuerpos que se unen al tl1a y sus usos
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
AR110526A1 (es) Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20161390A1 (es) Anticuerpos multiespecificos
EA201890028A1 (ru) Антитело, связывающее cd3 человека
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
PE20131209A1 (es) Anticuerpos anti-fap
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA201600277A1 (ru) Высокоаффиные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh